These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 865528)

  • 1. Theophylline disposition in patients with hepatic cirrhosis.
    Piafsky KM; Sitar DS; Rangno RE; Ogilvie RI
    N Engl J Med; 1977 Jun; 296(26):1495-7. PubMed ID: 865528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic aspects of theophylline in premature newborns.
    Aranda JV; Sitar DS; Parsons WD; Loughnan PM; Neims AH
    N Engl J Med; 1976 Aug; 295(8):413-6. PubMed ID: 934239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug disposition in liver disease.
    Shand DG
    N Engl J Med; 1977 Jun; 296(26):1527-8. PubMed ID: 865536
    [No Abstract]   [Full Text] [Related]  

  • 4. The theophylline disposition after caffeine administration in liver cirrhosis: an index of liver function.
    Hartleb M; Romańczyk T; Becker A; Mańczyk I; Waluga M; Spalińska M; Zieliński M
    Ital J Gastroenterol; 1992; 24(6):332-7. PubMed ID: 1515659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
    Orlando R; Padrini R; Perazzi M; De Martin S; Piccoli P; Palatini P
    Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites.
    Tanaka E; Ishikawa A; Yamamoto Y; Osada A; Tsuji K; Fukao K; Misawa S; Iwasaki Y
    Int J Clin Pharmacol Ther Toxicol; 1992 Sep; 30(9):336-41. PubMed ID: 1428297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cimetidine in patients with liver disease.
    González-Martin G; Arancibia A; Fajuri M; Chesta J; Novoa X
    Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):355-8. PubMed ID: 4030163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of theophylline in hepatic disease.
    Mangione A; Imhoff TE; Lee RV; Shum LY; Jusko WJ
    Chest; 1978 May; 73(5):616-22. PubMed ID: 648214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranitidine disposition in severe hepatic cirrhosis.
    Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic disposition of isoxicam in hepatic cirrhosis.
    Esquivel M; Ogilvie RI; East DS; Shaw DH; Heathcote J
    Clin Invest Med; 1987 Sep; 10(5):363-7. PubMed ID: 3677504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow].
    Nomura F; Ohnishi K; Ohto M; Takeda Y; Rikihisa T; Kanakubo Y
    Rinsho Byori; 1991 Oct; 39(10):1093-7. PubMed ID: 1762184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum metabolite/caffeine ratios as a test for liver function.
    Jodynis-Liebert J; Flieger J; Matuszewska A; Juszczyk J
    J Clin Pharmacol; 2004 Apr; 44(4):338-47. PubMed ID: 15051740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis.
    Cukier A; Strauss E; Terra Filho M; Santos SR; Vargas FS
    J Hepatol; 1992 May; 15(1-2):35-9. PubMed ID: 1506654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The disposition of theophylline in patients with lung and breast cancer.
    Corasaniti MT; Gatti G; Crema F; Attardo-Parrinello G; Barzaghi N; Perucca E
    Drugs Exp Clin Res; 1994; 20(3):115-20. PubMed ID: 7956718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction.
    Marshall JP; Salt WB; Elam RO; Wilkinson GR; Schenker S
    Gastroenterology; 1977 Dec; 73(6):1388-92. PubMed ID: 913979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral theophylline disposition in cystic fibrosis.
    Georgitis JW; Eigen H; Warner R; Gonzales MA
    Ann Allergy; 1982 Mar; 48(3):175-7. PubMed ID: 7065481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced peripheral conversion of thyroxine to triiodothyronine in patients with hepatic cirrhosis.
    Nomura S; Pittman CS; Chambers JB; Buck MW; Shimizu T
    J Clin Invest; 1975 Sep; 56(3):643-52. PubMed ID: 1159078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of famotidine after intravenous administration in liver disease.
    Ohnishi K
    Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipyrone metabolism in liver disease.
    Zylber-Katz E; Caraco Y; Granit L; Levy M
    Clin Pharmacol Ther; 1995 Aug; 58(2):198-209. PubMed ID: 7648770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of hepatic cirrhosis on the pharmacokinetics of theophylline in rats.
    Nam BH; Sohn DH; Ko G; Kim JB
    Arch Pharm Res; 1997 Aug; 20(4):318-23. PubMed ID: 18975172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.